Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org


Molecular Profile Unknown unknown
Therapy Mitomycin gel
Indication/Tumor Type renal pelvis transitional cell carcinoma
Response Type not applicable

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown renal pelvis transitional cell carcinoma not applicable Mitomycin gel FDA approved Actionable In a Phase III trial (OLYMPUS) that supported FDA approval, Jelmyto (mitomycin gel) treatment resulted in a complete response in 60% (41/68) of patients with low-grade upper tract urothelial cancer (J Urol. 2019 Apr; 201 (Supplement 4): abstract LBA-16; NCT02793128). detail...
PubMed Id Reference Title Details
NEPHRON-SPARING MANAGEMENT OF LOW GRADE (LG) UTUC WITH UGN-101 (MITOMYCIN GEL) FOR INSTILLATION: THE OLYMPUS TRIAL EXPERIENCE Full reference...